Rankings
▼
Calendar
TGTX FY 2022 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-58.4% YoY
Gross Profit
$3M
90.5% margin
Operating Income
-$218M
-7839.0% margin
Net Income
-$224M
-8036.3% margin
EPS (Diluted)
$-1.46
Cash Flow
Operating Cash Flow
-$176M
Free Cash Flow
-$176M
Stock-Based Comp.
$19M
Balance Sheet
Total Assets
$194M
Total Liabilities
$135M
Stockholders' Equity
$59M
Cash & Equivalents
$102M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$7M
-58.4%
Gross Profit
$3M
$6M
-57.3%
Operating Income
-$218M
-$345M
+36.7%
Net Income
-$224M
-$348M
+35.7%
← Q4 2021
All Quarters
Q1 2022 →